What is SEC Form 13F? Ultimate Guide to Institutional Equity Filings
Learn how SEC Form 13F filings work, the $100M threshold, 45-day reporting lag, and how to track top hedge fund holdings.
CIK: 0001465837
Total reported value
—
$2.0B
59 檔
32.6%
In Q1 2024, Boxer Capital, LLC's U.S. equity holdings reached a combined market value of $2.0B, distributed across 59 disclosed stock positions.
In Q1 2024, Boxer Capital, LLC displayed an active expansion posture, initiating 13 new positions and adding to 7 existing holdings, outstripping position reductions.
In terms of portfolio concentration, the top 5 core holdings (including SWTXUSD, CYTK, RVMD) accounted for 32.6% of total reported equity market value during Q1 2024.
| # | Ticker | Issuer | Asset Subclass | Weight | Weight Change | Shares Change | 4Q Trend |
|---|---|---|---|---|---|---|---|
| 1 | SWTXUSD | Springworks Therapeutics Inc | Stock-Other | 8.32% | -5.38% | EXIT | |
| 2 | CYTK | Cytokinetics Inc | Stock-Healthcare | 7.27% | -5.44% | EXIT | |
| 3 | RVMD | Revolution Medicines Inc | Stock-Healthcare | 6.81% | -9.52% | EXIT | |
| 4 | TYRA | Tyra Biosciences Inc | Stock-Other | 5.22% | -7.44% | EXIT | |
| 5 | APLSUSD | Apellis Pharmaceuticals Inc | Stock-Other | 5.01% | -2.44% | EXIT | |
| 6 | IDYA | Ideaya Biosciences Inc | Stock-Other | 4.77% | -3.42% | EXIT | |
| 7 | ✓ | Merus N V | Stock-Other | 4.23% | -4.66% | EXIT | |
| 8 | SRPT | Sarepta Therapeutics Inc | Stock-Healthcare | 4.16% | -3.98% | EXIT | |
| 9 | NUVL | Nuvalent Inc-a | Stock-Other | 4.15% | -5.62% | EXIT | |
| 10 | ONC | Beone Medicines Ltd-adr | Stock-Other | 3.86% | -5.51% | EXIT | |
| 11 | TNGX | Tango Therapeutics Inc | Stock-Other | 3.22% | -3.10% | EXIT | |
| 12 | NKTX | Nkarta Inc | Stock-Other | 2.99% | -0.89% | EXIT | |
| 13 | FATE | Fate Therapeutics Inc | Stock-Other | 2.98% | -0.85% | EXIT | |
| 14 | RNAGBP | Avidity Biosciences Inc | Stock-Other | 2.18% | -3.89% | EXIT | |
| 15 | AKRO | Akero Therapeutics Inc | Stock-Other | 2.09% | -2.36% | EXIT | |
| 16 | RCKT | Rocket Pharmaceuticals Inc | Stock-Other | 1.95% | -1.33% | EXIT | |
| 17 | ARGX | Argenx Se - Adr | Stock-Healthcare | 1.94% | -2.66% | EXIT | |
| 18 | LEGN | Legend Biotech Corp-adr | Stock-Other | 1.66% | -1.43% | EXIT | |
| 19 | AXSM | Axsome Therapeutics Inc | Stock-Healthcare | 1.58% | -1.76% | EXIT | |
| 20 | RCUS | Arcus Biosciences Inc | Stock-Other | 1.49% | -1.20% | EXIT | |
| 21 | ANAB | Anaptysbio Inc | Stock-Other | 1.45% | -2.14% | EXIT | |
| 22 | IMVT | Immunovant Inc | Stock-Other | 1.32% | -1.15% | EXIT | |
| 23 | XENE | Xenon Pharmaceuticals Inc | Stock-Other | 1.28% | -1.16% | EXIT | |
| 24 | ARVN | Arvinas Inc | Stock-Other | 1.24% | -0.74% | EXIT | |
| 25 | 2662247D | Iteos Therapeutics Inc | Stock-Other | 1.22% | -1.48% | EXIT | |
| 26 | VKTX | Viking Therapeutics Inc | Stock-Healthcare | 1.21% | — | — | |
| 27 | ORIC | Oric Pharmaceuticals Inc | Stock-Other | 1.18% | -0.87% | EXIT | |
| 28 | KURA | Kura Oncology Inc | Stock-Other | 1.05% | -0.96% | EXIT | |
| 29 | GERN | Geron CORP | Stock-Other | 0.98% | -1.34% | EXIT | |
| 30 | DAWNGBX | Day One Biopharmaceuticals I | Stock-Other | 0.97% | -0.81% | EXIT | |
| 31 | ✓ | Third Harmonic Bio Inc | Stock-Other | 0.93% | -1.33% | EXIT | |
| 32 | 4XC1 | Kalvista Pharmaceuticals Inc | Stock-Other | 0.93% | -0.90% | EXIT | |
| 33 | ALLO | Allogene Therapeutics Inc | Stock-Other | 0.85% | — | — | |
| 34 | GPCR | Structure Therapeutics Inc | Stock-Other | 0.85% | -0.86% | EXIT | |
| 35 | PRTA | Prothena Corporation plc | Stock-Other | 0.84% | -0.57% | EXIT | |
| 36 | SANA | Sana Biotechnology Inc | Stock-Other | 0.76% | -0.32% | EXIT | |
| 37 | RLAY | Relay Therapeutics Inc | Stock-Other | 0.75% | -0.63% | EXIT | |
| 38 | PSTXUSD | Poseida Therapeutics Inc | Stock-Other | 0.71% | — | — | |
| 39 | ✓ | Engene Holdings Inc | Stock-Other | 0.61% | — | — | |
| 40 | PRLD | Prelude Therapeutics Inc | Stock-Other | 0.60% | — | — | |
| 41 | ELVN | Enliven Therapeutics Inc | Stock-Other | 0.58% | -0.84% | EXIT | |
| 42 | IOVA | Iovance Biotherapeutics Inc | Stock-Other | 0.55% | -0.35% | EXIT | |
| 43 | JSPR | Jasper Therapeutics Inc | Stock-Other | 0.51% | -0.32% | EXIT | |
| 44 | BOLD | Boundless Bio Inc | Stock-Other | 0.50% | — | — | |
| 45 | SYRE | Spyre Therapeutics Inc | Stock-Other | 0.47% | -1.01% | EXIT | |
| 46 | IPSC | Century Therapeutics Inc | Stock-Other | 0.36% | -0.33% | EXIT | |
| 47 | ZNTL | Zentalis Pharmaceuticals Inc | Stock-Other | 0.35% | — | — | |
| 48 | AMLX | Amylyx Pharmaceuticals Inc | Stock-Other | 0.21% | — | — | |
| 49 | ABSI | Absci CORP | Stock-Other | 0.20% | — | — | |
| 50 | ATRAGBX | Atara Biotherapeutics Inc | Stock-Other | 0.14% | — | — |
| # | Ticker | Issuer | Weight Change | Shares Change | Action |
|---|---|---|---|---|---|
| 1 | FATE | Fate Therapeutics Inc | +2.9% | +1543.18% | Add |
| 2 | NKTX | Nkarta Inc | +2.5% | +289.40% | Add |
| 3 | SWTXUSD | Springworks Therapeutics Inc | +2.1% | — | Unchanged |
| 4 | RNAGBP | Avidity Biosciences Inc | +1.7% | +54.05% | Add |
| 5 | ✓ | Merus N V | +1.6% | — | Unchanged |
| 6 | VKTX | Viking Therapeutics Inc | +1.2% | NEW | New buy |
| 7 | KURA | Kura Oncology Inc | +1.1% | NEW | New buy |
| 8 | SRPT | Sarepta Therapeutics Inc | +1% | — | Unchanged |
| 9 | IDYA | Ideaya Biosciences Inc | +0.9% | — | Unchanged |
| 10 | ALLO | Allogene Therapeutics Inc | +0.9% | NEW | New buy |
| 11 | TYRA | Tyra Biosciences Inc | +0.8% | — | Unchanged |
| 12 | SANA | Sana Biotechnology Inc | +0.8% | NEW | New buy |
| 13 | PSTXUSD | Poseida Therapeutics Inc | +0.7% | NEW | New buy |
| 14 | RVMD | Revolution Medicines Inc | +0.7% | — | Unchanged |
| 15 | GERN | Geron CORP | +0.7% | +100.00% | Add |
| 16 | ✓ | Engene Holdings Inc | +0.6% | NEW | New buy |
| 17 | ✓ | Third Harmonic Bio Inc | +0.5% | +166.67% | Add |
| 18 | JSPR | Jasper Therapeutics Inc | +0.5% | NEW | New buy |
| 19 | BOLD | Boundless Bio Inc | +0.5% | NEW | New buy |
| 20 | ORIC | Oric Pharmaceuticals Inc | +0.4% | — | Unchanged |
| 21 | IPSC | Century Therapeutics Inc | +0.4% | NEW | New buy |
| 22 | 2662247D | Iteos Therapeutics Inc | +0.2% | — | Unchanged |
| 23 | AMLX | Amylyx Pharmaceuticals Inc | +0.2% | NEW | New buy |
| 24 | SYRE | Spyre Therapeutics Inc | +0.2% | — | Unchanged |
| 25 | ABSI | Absci CORP | +0.2% | NEW | New buy |
| 26 | AKRO | Akero Therapeutics Inc | +0.1% | — | Unchanged |
| 27 | ATRAGBX | Atara Biotherapeutics Inc | +0.1% | NEW | New buy |
| 28 | ELVN | Enliven Therapeutics Inc | +0.1% | +3.92% | Add |
| 29 | LABDUSD | Drx Dly S&p Biotech Bear 3x | +0.1% | NEW | New buy |
| 30 | DAWNGBX | Day One Biopharmaceuticals I | +0.1% | — | Unchanged |
| 31 | ANAB | Anaptysbio Inc | +0.1% | — | Unchanged |
| 32 | PRLD | Prelude Therapeutics Inc | +0.1% | — | Unchanged |
| 33 | NUVL | Nuvalent Inc-a | 0% | — | Unchanged |
| 34 | ✓ | Rain Oncology Inc Com | -0.1% | EXIT | Sold out |
| 35 | 4XC1 | Kalvista Pharmaceuticals Inc | -0.1% | -3.64% | Trim |
| 36 | KOD | Kodiak Sciences Inc | -0.1% | EXIT | Sold out |
| 37 | XENE | Xenon Pharmaceuticals Inc | -0.1% | — | Unchanged |
| 38 | LEGN | Legend Biotech Corp-adr | -0.1% | — | Unchanged |
| 39 | APLSUSD | Apellis Pharmaceuticals Inc | -0.1% | — | Unchanged |
| 40 | RCKT | Rocket Pharmaceuticals Inc | -0.2% | — | Unchanged |
| 41 | RLAY | Relay Therapeutics Inc | -0.3% | — | Unchanged |
| 42 | PRTA | Prothena Corporation plc | -0.4% | +3.76% | Add |
| 43 | ONC | Beone Medicines Ltd-adr | -0.6% | — | Unchanged |
| 44 | IMVT | Immunovant Inc | -0.8% | -17.50% | Trim |
| 45 | TNGX | Tango Therapeutics Inc | -0.8% | — | Unchanged |
| 46 | ARGX | Argenx Se - Adr | -1.1% | -37.50% | Trim |
| 47 | CYTK | Cytokinetics Inc | -1.5% | — | Unchanged |
| 48 | ✓ | -3.9% | EXIT | Sold out | |
| 49 | IMGNEUR | Immunogen Inc | -4.4% | EXIT | Sold out |
| 50 | MRTXEUR | Mirati Therapeutics Inc | -9.4% | EXIT | Sold out |
According to official SEC Form 13F filings, Boxer Capital, LLC reported a total U.S. public equity portfolio value of $2.0B across 59 disclosed positions in Q1 2024.
During Q1 2024, Boxer Capital, LLC's top holdings by market value included SWTXUSD (8.3%)、CYTK (7.3%)、RVMD (6.8%). The largest single position, SWTXUSD, represented 8.3% of total portfolio value.
Expert Analysis & Guides for Tracking Wall Street Smart Money Movements
Learn how SEC Form 13F filings work, the $100M threshold, 45-day reporting lag, and how to track top hedge fund holdings.
Top New Position Initiated
VKTX
市值: $24.6M
Top Position Liquidated / Trimmed
MRTXEUR
前期市值: $188.1M
In Q1 2024, Boxer Capital, LLC made 28 total portfolio adjustments, initiating 13 new buys, adding to 7 positions, trimming 3 holdings, and fully liquidating 5 stocks.
All holding records on this page are fetched directly from the U.S. Securities and Exchange Commission (SEC) EDGAR system (Form 13F-HR). AlphaSMO parses CUSIP identifiers and formats data into Schema.org-compliant datasets.
Understand SEC Form 4 insider disclosures for corporate officers, directors, and 10% owners to track executive transactions.
Understand Rule 144 restricted stock sale notices to spot planned insider liquidations before market sell pressure arrives.
Explore the 5% beneficial ownership threshold, 13D vs 13G filing differences, and recent SEC accelerated deadline rules.
Best practices for analyzing 13F quarterly changes without getting misled by stock splits, options, or market valuation drift.
Learn how AlphaSMO's flagship signal detects high-conviction stocks where 13F hedge funds and corporate insiders buy at the same time.